Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

abemaciclib

- PMLiVE

Almirall granted EC approval for Ebglyss in moderate-to-severe atopic dermatitis

The inflammatory skin disease currently affects an estimated 4.4% of adults in the EU

- PMLiVE

AstraZeneca’s Truqap plus Faslodex receives FDA approval for advanced breast cancer

About 290,000 people in the US will be diagnosed with breast cancer in 2023

- PMLiVE

Eli Lilly’s tirzepatide injection approved by MHRA and FDA for weight loss in adults

The drug has been authorised for use alongside a reduced-calorie diet and physical activity

- PMLiVE

MHRA authorises anastrozole to prevent breast cancer in post-menopausal women

The treatment could help prevent around 2,000 breast cancer cases in England

- PMLiVE

Eli Lilly exercises option to progress autoimmune and inflammatory disease therapy

The move triggers an undisclosed milestone payment to Lilly’s partner Sitryx Therapeutics

- PMLiVE

Eli Lilly’s Omvoh granted FDA approval for ulcerative colitis

Inflammatory bowel disease is estimated to affect nearly one in every 100 people in the US

- PMLiVE

Eli Lilly and Almirall’s lebrikizumab shows sustained improvements in atopic dermatitis

The IL-13 inhibitor improved the symptoms of atopic dermatitis for up to two years

- PMLiVE

Merck shares positive results for Keytruda in early-stage breast cancer

Approximately 298,000 people will be diagnosed with breast cancer in the US this year

- PMLiVE

Eli Lilly to acquire cancer specialist Point Biopharma in deal worth $1.4bn

The transaction would give Lilly access to experimental radioligand therapies

- PMLiVE

Further data for AstraZeneca/Daichii Sankyo’s Enhertu requested by NICE

Enhertu is currently approved for HER2-low metastatic breast cancer in over 30 countries

- PMLiVE

ScreenPoint Medical to showcase AI software at European scientific meeting

Trial results show that the software boosts breast cancer detection by 20%

- PMLiVE

AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study

More than two million people worldwide are diagnosed with breast cancer every year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links